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ABSTRACT
Introduction: Rotavirus is the most common cause of
severe gastroenteritis in infants and young children
worldwide. Currently 67 countries include rotavirus
vaccine in childhood immunisation programmes, but
uptake in Western Europe has been slow. In July 2013,
rotavirus vaccine was introduced into the UK’s routine
childhood immunisation programme. Prior to vaccine
introduction in the UK, rotavirus was estimated to result
in 750 000 diarrhoea episodes and 80 000 general
practice (GP) consultations each year, together with 45%
and 20% of hospital admissions and emergency
department attendances for acute gastroenteritis, in
children under 5 years of age. This paper describes a
protocol for an ecological study that will assess rotavirus
vaccine impact in the UK, to inform rotavirus
immunisation policy in the UK and in other Western
European countries.
Methods and analysis: In Merseyside, UK, we will
conduct an ecological study using a ‘before and after’
approach to examine changes in gastroenteritis and
rotavirus incidence following the introduction of rotavirus
vaccination. Data will be collected on mortality, hospital
admissions, nosocomial infection, emergency
department attendances, GP consultations and
community health consultations to capture all healthcare
providers in the region. We will assess both the direct
and indirect effects of the vaccine on the study
population. Comparisons of outcome indicator rates will
be made in relation to vaccine uptake and socioeconomic
status.
Ethics and dissemination: The study has been
approved by NHS Research Ethics Committee, South
Central-Berkshire REC Reference: 14/SC/1140. Study
outputs will be disseminated through scientific
conferences and peer-reviewed publications. The study
will demonstrate the impact of rotavirus vaccination on
the burden of disease from a complete health system
perspective. It will identify key areas that require
improved data collection tools to maximise the
usefulness of this surveillance approach and will provide
a template for vaccine evaluations using ecological
methods in the UK.
INTRODUCTION
Rotavirus is the most common cause of severe
gastroenteritis in infants and young children,
responsible for an estimated annual 453 000
deaths worldwide among children under age
5 years, with over 90% of deaths occurring in
the developing countries.1 In the UK, rota-
virus gastroenteritis (RVGE) is seasonal and
most cases occur between February and April
each year. Rotavirus is estimated to result in
750 000 diarrhoea episodes and 80 000
Strengths and limitations of this study
▪ Strengths include use of data from multiple
health systems that will allow examination of the
relative impact of vaccination on the various
health providers and communities rather than
the individual. These multiple data sources will
provide robustness, enabling easier identification
of outliers from overall trends.
▪ The study will include all ages for rotavirus and
all-cause gastroenteritis incidence for 3 years
postvaccination, thereby minimising confounding
caused by yearly variance in rotavirus numbers.
▪ Additionally the study is powered to measure the
indirect (herd) effect on hospital admissions,
and while the majority of studies have focused
on this, this study will also provide evidence for
the indirect effect in emergency departments and
community settings.
▪ The study will be limited by the ecological before
and after design, and the difficulties of ascribing
causality to vaccine, as well as the inherent risks
of bias and confounding in observational studies
particularly due to underlying secular trends.
▪ Use of syndromic indicators that are non-specific
to rotavirus will limit the study to measuring
large effects rather than small variations for
emergency departments and community health
outcome measures.
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general practice (GP) consultations each year in the UK,2
together with 45% and 20% of hospital admissions and
emergency department (ED) attendances for acute
gastroenteritis (AGE), respectively, in children under
5 years of age.3 The economic cost of RVGE to the health
service is estimated to be approximately £14 million per
year in England and Wales.3 At Alder Hey Children’s
NHS Foundation Trust, Liverpool, UK, rotavirus is a
major cause of community-acquired and healthcare-asso-
ciated diarrhoea; in a 2-year prospective study among hos-
pitalised children, rotavirus was detected by RT-PCR in
43% of community-acquired and in 31% of healthcare-
associated gastroenteritis cases.4 AGE hospital admissions
are known to have a positive correlation with socio-
economic deprivation5 and globally the burden of severe
RVGE is much higher in low-income countries. However,
RVGE has not yet been correlated with socioeconomic
deprivation in the UK.
In July 2013, the Department of Health introduced a
rotavirus vaccine into the UK’s routine childhood
immunisation programme.6 7 The live-attenuated,
two-dose oral monovalent vaccine (Rotarix,
GlaxoSmithKline Biologicals, Belgium) is administered at
2 and 3 months of age. Clinical trials in Europe and the
Americas with both currently licensed rotavirus vaccines
(Rotarix and a pentavalent vaccine RotaTeq developed by
Merck) led to a WHO recommendation in 2007 to vaccin-
ate children in these regions.8–10 Subsequent trials in
Africa and Asia led to an extension of the recommenda-
tion to include all children worldwide.10–12 At present
more than 60 countries include a rotavirus vaccine in
childhood immunisation programmes.13 Introduction of
rotavirus vaccination in Western Europe has been slow
however, with only Austria, Belgium, Finland, Luxemburg
and most recently the UK having rolled out universal
rotavirus vaccination programmes to date.14 Based on the
uptake of other routine childhood vaccinations in the
UK, coverage of over 90% would be expected for rota-
virus vaccine;15 initial ﬁgures for England indicate 93%
uptake for ﬁrst dose and 88% for the second dose of rota-
virus vaccine.16
Clinical trials in middle-income and high-income coun-
tries demonstrated high (>85%) efﬁcacy against severe
RVGE.10 The introduction of rotavirus vaccines in the
immunisation programmes of these countries has
demonstrated direct beneﬁts on a par with those
observed in clinical trials, with signiﬁcant reductions in
diarrhoea hospitalisations.17 An unanticipated but bene-
ﬁcial consequence of rotavirus vaccination has been the
reduction of rotavirus disease in unvaccinated individuals
(herd protection), likely due to reduced virus transmis-
sion. Such ‘indirect beneﬁts’ include reduced disease in
non-vaccinated older children and adults who were not
thought to sustain a signiﬁcant burden of rotavirus
disease.18 In the UK, the burden of RVGE in older chil-
dren and adults is difﬁcult to estimate but admissions for
AGE are 2 per 1000 population in 5–14-year-olds and 7
per 1000 in those 15+ years.19 Hence monitoring changes
in AGE incidence in non-vaccinated older children and
adults is critical to assess indirect impact.
Ecological rotavirus vaccine effectiveness studies have
primarily focused on mortality, hospitalisations and
laboratory detections as a measure of burden.20–27
Severe cases of rotavirus infection will often end up in
hospital and receive full diagnostic evaluation. However,
many cases of rotavirus infection, particularly in older
children and adults, will not attend hospital but will be
seen by primary and community healthcare providers.
Therefore, in order to better understand the burden of
RVGE and AGE on all ages and the impact of routine
immunisation on the health system, it is crucial to
examine routine data sources for all health service provi-
ders in a deﬁned study area. Taking advantage of a
range of regional healthcare facilities in Merseyside, UK,
we describe a protocol for an ecological study which will
use a ‘before and after’ approach allowing comprehen-
sive evaluation of the direct and indirect vaccine impact
following the introduction of the monovalent rotavirus
vaccine into the UK’s routine childhood immunisation
programme. We will investigate the relationship between
socioeconomic deprivation, and vaccine uptake and
disease burden. These data will provide evidence to
support future rotavirus vaccination in the UK and will
inform rotavirus immunisation policy in other Western
European countries.6
METHODS
Study aim
Routine data sources will be used to estimate the direct
and indirect effects of monovalent rotavirus vaccination
on gastroenteritis indicators in the population of
Merseyside, UK, and their relationship to vaccine cover-
age and sociodemographic indicators. We also hope to
identify the key areas that require extended and
improved data collection tools to maximise the useful-
ness of this surveillance approach. The main outcome
measures are:
▸ Laboratory detections of rotavirus in faecal samples;
▸ Admissions to hospital for RVGE or AGE;
▸ Attendances to EDs for AGE;
▸ Number of nosocomially acquired cases of RVGE;
▸ GP and community consultations for diarrhoea and
AGE in children less than 5 and in all ages;
▸ Routine rotavirus vaccine coverage mapping by small
area geography;
▸ Relative contribution of direct (those vaccinated) and
indirect (not vaccinated) effects to overall vaccine
beneﬁt in health system usage for both RVGE and
AGE;
▸ Relationship between socioeconomic deprivation,
vaccine uptake and RVGE/AGE incidence.
Study setting and location
The study will be conducted in the large metropolitan
area of Merseyside in North West England which
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contains the city of Liverpool. Merseyside has a popula-
tion of nearly 1.4 million people, with approximately
80 000 of its population under 5 years of age.
Socioeconomic deprivation within Merseyside is variable
but over 60% of its population live in a more socio-
economically deprived area than the England average
(ﬁgure 1).28 Vaccination uptake for most routine child-
hood vaccinations is also variable in small areas, but
overall Merseyside has uptake above the average for
England.15 Healthcare for the population is self-
contained with the region and including a specialist
paediatric hospital. Further detail of healthcare provi-
sion is provided below.
Study overview and choice of study designs
The study will employ an ecological design, utilising
routine health surveillance data before and after rota-
virus vaccine introduction. The evaluation incorporates
interrupted time series analyses of outcome indicators
across the study population. Comparisons of outcome
indicator rates will be made between communities with
high vaccine uptake and those with lower vaccine uptake
and the relationship with socioeconomic deprivation.
The ecological study approach allows population-based
rates of outcomes to be compared in space and time
using vaccine uptake and community-level socio-
economic deprivation as covariates.
Study data
The National Health Service (NHS) in England and
other government service agencies collect a range of
administrative and healthcare data which is held at both
local service level and centrally. Figure 2 outlines the
data sources that will be used for the evaluation and
table 1 shows the case deﬁnitions.
Hospital admission and ED attendance data will be
obtained from hospital episode statistics (HES),19 which
record all inpatient admissions in NHS hospitals in
England. The study will therefore measure hospitalisa-
tions and ED attendances for residents of Merseyside
receiving care in hospitals throughout England.
The study will obtain GP consultation data for diar-
rhoea or gastroenteritis from Clinical Commissioning
Groups covering Merseyside or from government held
sentinel surveillance systems. Community consultations
for diarrhoea and gastroenteritis at ‘Walk-in Centres’ will
be sourced from NHS Community Health Trusts. Walk-in
Centres are primarily nurse-led primary care facilities for
illness and injuries without need for prior appointment.
RVGE at Alder Hey Children’s NHS Foundation Trust
(Alder Hey) in Liverpool is classiﬁed as community
acquired or nosocomial. Alder Hey’s footprint covers the
majority of Merseyside’s children, so these data will
enable evaluation of the effect of rotavirus vaccination
on nosocomial rotavirus infection in children across
Merseyside.
Laboratory detections of rotavirus from Public Health
England Laboratory surveillance covering Merseyside
residents will be included in the analysis. Other causative
agents of AGE identiﬁed through laboratory testing
including, for example, norovirus, adenovirus and astro-
virus will also be extracted for analysis.
Each data set will cover at least 3 years either side of
vaccine introduction. All data will be pseudoanonymised
to allow distinction of records but no linking of data sets
or identiﬁcation of individuals will be undertaken. All
data will be either geocoded from postcode to small stat-
istical geographical community units termed Lower
Super Output Areas (LSOAs) or sourced with this geog-
raphy. LSOAs consist of approximately 1500 persons and
denominator populations will be derived from the
Ofﬁce of National Statistics (ONS) mid-year population
estimates by LSOA.29 Indicators of socioeconomic
deprivation at LSOA level will be measured using the
English Indices of Deprivation. The UK Department for
Communities and Local Government produce the
English Indices of Deprivation using census and other
local administrative data.28 Rotavirus vaccination uptake
data will be sourced from the Child Health Information
System (CHIS) which is held by community NHS health
Trusts in Merseyside. Records of doses of vaccinations
given as part of the UK childhood vaccine schedule are
recorded in CHIS for each child.
Quality control
Data sources such as HES and laboratory detections will
be inﬂuenced by testing practices; for instance, testing
of some organisms is more likely to occur at certain
times of the year. In the hospital admission data set, it is
possible that some cases of RVGE will not be coded as
rotaviral enteritis (ICD10: A08.0) and may be classiﬁed
as other unspeciﬁed either due to an absence of labora-
tory conﬁrmation or misclassiﬁcation/miscoding. In
order to attempt to quantify this information bias, the
investigator team will perform quality control on hos-
pital admissions and laboratory detections at the lead
NHS Trust hospital site (Alder Hey). Using a sample of
cases from at least 3 years, those cases with a laboratory
conﬁrmation will be checked against clinical records
and clinic coding and those coded as ICD10 A08.0 rota-
viral enteritis will be cross-matched against laboratory
detections. Based on the results of this assessment, it
may be necessary to adjust the recorded number of hos-
pital admissions for any ascertainment bias identiﬁed.
Ethical considerations
The study has been approved by NHS Research Ethics
Committee, South Central-Berkshire REC Reference:
14/SC/1140. Data sharing agreement will be obtained
between PHE, participating NHS Trusts and the
University of Liverpool. Research governance approval
will be sought form all participating NHS Trusts and
Clinical Commissioning Groups.
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Data analysis
Changes in trends of primary care consultations, com-
munity consultations, ED attendances, hospitalisations
and rotavirus detections will be explored using inter-
rupted time series analysis. Moving averages will be
examined to highlight any long-term trends while
smoothing out any short-term ﬂuctuations. Standardised
population-based rates for a minimum of a 3-year period
prior to vaccination and year on year after vaccination
(for 3 years) will be compared. For the regression ana-
lysis, Poisson regression will be used. We will ﬁrst
compute monthly population-based rates that are
‘expected’ to occur in the absence of a rotavirus vaccin-
ation programme by ﬁtting the model to prevaccine
data. We will then adjust for seasonality. The model will
be used to estimate ‘expected’ population-based rates
after vaccination and we will then compare with
‘observed’ population-based rates. We will then calculate
rate ratios and assess the magnitude of decline in rates.
Using a Poisson regression model, and including demo-
graphic and vaccine uptake indicators, we would be able
to predict impact of vaccination on the AGE and RVGE
indicators at various services and vaccine uptake levels.
Potential data biases will be controlled for by the access
and analysis multiple health data sources over a
minimum of 6 years.
Environmental factors which may inﬂuence rotavirus inci-
dence and seasonality are difﬁcult to identify or indeed
quantify. To account for any potential environmental con-
founders, correlation of laboratory conﬁrmations of viral
gastroenteritis-causing organisms (eg, norovirus, astrovirus)
with rotavirus laboratory conﬁrmations will be established.
If a signiﬁcant correlation between any other viral gastro-
enteritis and rotavirus can be identiﬁed, the resulting cor-
relation coefﬁcients will be used to estimate relative
contribution of vaccination and undeﬁned environmental
factors to any changes in rotavirus incidence. Furthermore,
we will explore a potential reciprocal increase in other viral
agents (eg, norovirus) due to a decrease in circulating rota-
virus, and potential increase in susceptible individuals par-
ticularly in those under 5 years of age.
Power calculation
Based on hospital admissions for RVGE in 2012
obtained from HES data, the estimated rate of RVGE
hospitalisation is approximately 1 per 1000 children
Figure 1 Socioeconomic deprivation in Merseyside. Produced using the English Indices of Deprivation 2010, national quintiles
for the Index of Multiple Deprivation.19
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under age 5 years in England.19 Assuming high vaccine
uptake rates (ie, 95%), similar to uptake of other
routine childhood vaccines in Merseyside, we used a one
sample comparison of proportions for a two-sided test to
calculate the power estimates (table 2). Studies from
other high-income countries on the population effects
of rotavirus vaccination have shown reductions in hos-
pital admissions of over 50% in children under 5 years
of age.14 Assuming a similar reduction in Merseyside,
this study has over 90% power to detect a signiﬁcant
change in RVGE hospital admissions.
The study is also powered for detecting an indirect
effect in adults. Using an AGE hospital admission rate of
7 per 1000 population aged 15+ years,19 we would expect
power to be at least 0.97 for Merseyside at assumed hospi-
talisation rate reductions post vaccination of 5%, 8% and
10%. Additionally, for GP consultations for AGE in chil-
dren under 5, a power of 0.89 and 1 can be achieved, for
assumed consultation rate reductions post vaccination of
5% and 10% respectively. No formal power calculations
have been undertaken for other end points under study.
Timeline
The study will be conducted over a 3-year period begin-
ning in April 2014. Prior to the start of the study, admin-
istrative procedures will be undertaken including data
sharing agreements, consultation with data providers,
database development for storing all sourced data, data
analysis and report writing (including interim yearly,
ﬁnal and peer review papers).
Project governance
A stakeholder group within Merseyside will be estab-
lished to enable effective achievement of the project
objectives and ownership by the professional community.
The stakeholder group will include representatives from:
Liverpool Health Partners;30 Liverpool Community
Health NHS Trust;31 NHS England Merseyside Area
Team Screening and Immunisation Team;32 Alder Hey
Children’s NHS Foundation Trust33 and Public Health
England34-Liverpool.
Dissemination of research findings
The ﬁndings will be presented at professional and scien-
tiﬁc conferences. The results will also be published in
peer review publications. Interim and ﬁnal reports will
be submitted to the funders and the stakeholder group.
DISCUSSION
This study will enable demonstration of a complete
health system perspective of the impact of rotavirus
Figure 2 Schematic of study data sources and outcome measures. Data sources cover a variety of healthcare providers at
different levels of the health system. This shows from which data sources outcome measures will be obtained (LSOA, Lower
Super Output Area).
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vaccination on the burden of disease in Merseyside, UK.
It aims to study both direct and indirect effects of
routine rotavirus vaccination. The study will also enable
data on vaccine efﬁcacy to infer the relative contribution
of RVGE to AGE primary care, and emergency care con-
sultations. Furthermore as data will be linked to speciﬁc
geographical units, for which information on socio-
economic deprivation and vaccine uptake is available,
we will be able to explore the association of these with
disease burden. Quality control procedures contained
within the study will provide a means of adjusting ana-
lysis for information bias and also enable identiﬁcation
of the key data collection issues that require improve-
ment to maximise the usefulness of this surveillance
approach. It is also hoped that this study will provide a
learning resource and template for similar ecological
approaches to examine effectiveness of other vaccines in
the UK in the future.
Strengths
A whole health system approach in a geographically
deﬁned area provides a number of strengths. Using data
sets from a range of healthcare providers within a health
economy will allow us to examine the relative impact of
vaccination on the various health providers rather than
the individual. The use of multiple data sources to
measure independent indicators of vaccination effect
will also provide robustness, enabling easier identiﬁca-
tion of outliers from overall trends.
Since there is annual variability in the number of rota-
virus cases, it is imperative to conduct surveillance of rota-
virus incidence over a number of years prevaccine and
postvaccine introduction. This study will provide a mech-
anism to do this as it will cover three rotavirus seasons
postvaccine introduction. Thus, cofounding caused by
yearly variance in rotavirus numbers will be minimised.
There are limited published data describing the indir-
ect effect of routine vaccination on unvaccinated older
children and adults and the majority of studies have
focused on hospital admissions. As this study will collect
data for all ages and cover RVGE and AGE incidence
3 years postvaccination, it will provide sufﬁcient data for
measurement of the indirect effect on hospital admis-
sions. Additionally, while the majority of studies into the
Table 1 Case definitions by health data set
Data set Case definition
Nosocomial and community
acquired
Nosocomial—laboratory-confirmed rotavirus case. Gastroenteritis symptoms beginning
more than 2 days after admission
Community acquired—laboratory-confirmed rotavirus case. Gastroenteritis symptoms
starting within 2 days of admission
Hospital admissions Rotavirus case definition—inpatient FCE with a primary or subsidiary diagnosis ICD10
diagnosis code of A08.0
AGE case definition—inpatient FCE with a primary or subsidiary diagnosis ICD10 code of
A08–A09
Emergency department
attendances
Attendance with a primary or secondary diagnosis code Z:III Gastrointestinal conditions––
other (those subsequently admitted excluded to prevent duplication in hospital admissions)
GP consultations GP consultations (Read codes in parenthesis): diarrhoea and vomiting (19G); diarrhoea
symptom NOS (19F6), viral gastroenteritis (A07y0), diarrhoea (19F2); gastroenteritis—
presumed infectious origin (A0812), diarrhoea of presumed infectious origin (A083);
infantile viral gastroenteritis (A07y1); infectious gastroenteritis (A0803); enteritis due to
rotavirus (A0762); and infectious diarrhoea (A082). Viral gastroenteritis will be used as the
primary case definition but diarrhoea/vomiting will be used for a secondary indicator of
burden
Community consultations
(Walk-in Centres)
There is no coding system for diagnosis in Walk-in Centre data. Therefore, the description
of patient symptoms field will be queried using the following key words: diarrhoea,
vomiting, GI and gastroenteritis. A Soundex script will be used to allow for spelling
inaccuracies
Laboratory detections Detection of rotavirus in a faecal specimen by a standard assay
Detection of other AGE causative organisms
FCE, finished consultant episodes; GP, general practice; ICD10, International Classification of Disease V.10.
Table 2 Predicted power of study for main outcome (hospitalisation rate) in Merseyside and selected subdistricts
Area
Population
(children <5 years)
Assumed reduction in rotavirus hospitalisation rate
25% 30% 40% 50% 75%
Liverpool 27 000 0.22 0.31 0.56 0.82 1
Liverpool and Sefton 41 000 0.34 0.48 0.78 0.96 1
Liverpool, Sefton and Knowsley 50 000 0.41 0.58 0.87 0.99 1
Merseyside 80 000 0.63 0.8 0.98 1 1
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indirect effect of vaccination have focused on hospital
admissions, this study will examine indirect effects in
EDs and community settings. This is particularly import-
ant as it is perhaps more likely that moderate/severe
RVGE in unvaccinated older children and adults will be
treated at EDs and through community consultations.
Another potential strength of the study is the ability to
conduct analysis at small community (LSOA) level. This
will enable small area sociodemographic information
such as socioeconomic deprivation to be included in the
analyses as a covariate at the lowest possible unit of ana-
lyses other than the individual. Thus, allowing the
exploration of the association between socioeconomic
deprivation, burden of RVGE/AGE and vaccine uptake
while limiting the ecological fallacy of analysis.
As many of the data sources included in this study do
not include speciﬁc RVGE classiﬁcation, we will be using
AGE as an outcome measure for most data sets.
Laboratory detection data which are organism speciﬁc will
allow us to adjust these measures based on the seasonal
contribution of organisms other than rotavirus such as
norovirus. For example, RVGE seasonality is fairly constant
but that of norovirus tends to vary over the winter and
spring months in the UK. These AGE indicators can there-
fore be adjusted for changes in norovirus seasonality
(ﬁgure 3)35 to give a better proxy of the contribution of
rotavirus to overall AGE causes and the relative impact of
rotavirus vaccination.
Limitations
The gold standard for measurement of vaccine efﬁcacy
is the randomised controlled trial. However, this
ecological study will investigate the impact of vaccination
on population disease burden within a health system;
therefore, an ecological study is appropriate. Conversely it
is recognised that an ecological approach cannot show
individual-level effects of vaccine and can only infer the
impact of the vaccine at the population level without caus-
ation. Additionally, a key focus of this study will be to
quantify variation in the outcomes measured according to
vaccine uptake levels and socioeconomic deprivation.
Confounding may be an issue since cases living in areas
with low vaccine uptake or high socioeconomic depriv-
ation may also have other characteristics that will affect
the risk of RVGE or AGE.
For measures of AGE activity in community settings
(eg, GP and Walk-in Centre), we will use syndromic indi-
cators that are non-speciﬁc to rotavirus, for example,
diarrhoea, vomiting. An inherent issue is that the ability
to detect effect on these is likely to be limited to large
effects rather than small variations.
A further limitation of the study is that investigators
will not collect data directly as all data are secondary,
with consequent risk of bias. There is potential for clin-
ical coding to lead to misclassiﬁcation of disease, and
this misclassiﬁcation may vary by different data sources.
We will describe these biases through quality control and
subsequently adjust for them at the analysis stage. The
use of multiple data sets for outcome indicators limits
these issues by improving robustness.
It is likely that there have been changes in data collec-
tion methods over the study period, for example,
changes to the assay used for rotavirus laboratory testing,
leading to testing bias. One way to adjust for this in the
Figure 3 Laboratory detections of rotavirus and norovirus in the North West, England, 2009/10–2013–14. Laboratory reports are
from LabBase2 system at Public Health England,35 showing variation in the norovirus season as compared to the rotavirus season.
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analysis is to pool data over a number of years to smooth
ﬂuctuations caused by changes in testing methods. The
investigators will identify changes through contact with
rotavirus testing laboratories and NHS Trusts, so that
changes may be described and where possible assist
appropriate analytical adjustments. It is also feasible that
the introduction of vaccination may also trigger changes
in clinician requests for rotavirus and other AGE diagnos-
tic testing, particularly in the vaccination age group. Any
possible testing bias will be assessed at the lead NHS Trust
via comparisons with prevaccine testing probabilities.
The study currently will not include any economic
component. However, previous studies have reported the
likely cost-effectiveness of rotavirus vaccination for the
population under 5 years of age.36 This study will
provide the results and data necessary for economic
evaluation based on the direct and indirect impact of
rotavirus vaccination.
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